Your browser is no longer supported. Please, upgrade your browser.
IMUX Immunic, Inc. daily Stock Chart
Immunic, Inc.
Index- P/E- EPS (ttm)-15.70 Insider Own- Shs Outstand10.30M Perf Week-6.33%
Market Cap86.83M Forward P/E- EPS next Y-2.79 Insider Trans- Shs Float9.81M Perf Month-31.85%
Income-33.40M PEG- EPS next Q-0.67 Inst Own15.40% Short Float0.29% Perf Quarter-37.09%
Sales- P/S- EPS this Y25.10% Inst Trans0.13% Short Ratio0.81 Perf Half Y-48.22%
Book/sh7.18 P/B1.17 EPS next Y26.30% ROA-113.30% Target Price45.00 Perf Year-29.49%
Cash/sh3.50 P/C2.41 EPS next 5Y15.50% ROE-127.20% 52W Range6.04 - 46.80 Perf YTD13.12%
Dividend- P/FCF- EPS past 5Y12.00% ROI- 52W High-81.79% Beta3.58
Dividend %- Quick Ratio12.60 Sales past 5Y- Gross Margin- 52W Low41.06% ATR0.75
Employees10 Current Ratio12.60 Sales Q/Q- Oper. Margin- RSI (14)28.96 Volatility4.25% 7.84%
OptionableYes Debt/Eq0.00 EPS Q/Q87.30% Profit Margin- Rel Volume0.41 Prev Close8.43
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume35.80K Price8.52
Recom1.50 SMA20-12.10% SMA50-31.17% SMA200-27.01% Volume9,150 Change1.07%
Jul-11-19Initiated Chardan Capital Markets Buy $40
Oct-17-19 08:45AM  We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully Simply Wall St.
Oct-15-19 06:30AM  Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson PR Newswire
Oct-10-19 04:01PM  Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis PR Newswire
Sep-30-19 06:30AM  Immunic, Inc. to Participate in Investor and Scientific Conferences in October PR Newswire -6.88%
Sep-18-19 06:30AM  Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist PR Newswire
Sep-11-19 06:30AM  Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019 PR Newswire
Sep-05-19 04:00PM  Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range PR Newswire
Sep-03-19 06:30AM  Immunic, Inc. to Participate in Scientific and Investor Conferences in September PR Newswire -6.53%
Aug-12-19 06:30AM  Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis PR Newswire
Aug-08-19 06:30AM  Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity PR Newswire
Aug-01-19 06:30AM  Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project PR Newswire
Jul-30-19 06:30AM  Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8 PR Newswire +11.46%
Jul-19-19 11:53AM  Could Immunic, Inc.'s (NASDAQ:IMUX) Investor Composition Influence The Stock Price? Simply Wall St.
Jul-16-19 06:30AM  Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer PR Newswire -6.09%
Jun-24-19 06:30AM  Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston PR Newswire +90.86%
Jun-21-19 08:30AM  Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update PR Newswire -5.01%
Jun-04-19 06:30AM  Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2 Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway PR Newswire +10.18%
May-30-19 06:30AM  Immunic, Inc. to Participate in Investor and Scientific Conferences in June PR Newswire
May-09-19 06:30AM  Immunic, Inc. to Participate in Upcoming May Conferences PR Newswire
Apr-29-19 06:30AM  Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer PR Newswire
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.